In a case report of ketoacidosis resulting from an injection of Wegovy 1.7 mg for the treatment of type 1 diabetes mellitus (T1DM), the effects of appetite suppression and inhibition of gluconeogenesis and glycogenolysis produced by GLP-1 RAs contributed to the reduction of the patient’s insulin push and induced the development of diabetic keto acidosis. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.